BioCryst Pharmaceuticals BCRX Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's unrealized losses on investments (before tax)?
- BioCryst Pharmaceuticals (BCRX) reported unrealized losses on investments (before tax) of $95K in Q1 2026.
- How has BioCryst Pharmaceuticals's unrealized losses on investments (before tax) changed year-over-year?
- BioCryst Pharmaceuticals's unrealized losses on investments (before tax) increased by 2275.0% year-over-year, from $4K to $95K.
- What is the long-term trend for BioCryst Pharmaceuticals's unrealized losses on investments (before tax)?
- Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's unrealized losses on investments (before tax) has grown at a -83.2% compound annual growth rate (CAGR), from $1.06M to $5K.